U.S. markets closed
  • S&P 500

    4,591.67
    +53.24 (+1.17%)
     
  • Dow 30

    35,227.03
    +646.95 (+1.87%)
     
  • Nasdaq

    15,225.15
    +139.68 (+0.93%)
     
  • Russell 2000

    2,203.48
    +44.17 (+2.05%)
     
  • Crude Oil

    69.93
    +3.67 (+5.54%)
     
  • Gold

    1,777.30
    -4.70 (-0.26%)
     
  • Silver

    22.38
    -0.07 (-0.31%)
     
  • EUR/USD

    1.1288
    -0.0029 (-0.26%)
     
  • 10-Yr Bond

    1.4340
    +0.0910 (+6.78%)
     
  • GBP/USD

    1.3260
    +0.0025 (+0.19%)
     
  • USD/JPY

    113.5020
    +0.7020 (+0.62%)
     
  • BTC-USD

    49,014.87
    +350.30 (+0.72%)
     
  • CMC Crypto 200

    1,270.51
    +10.35 (+0.82%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    27,927.37
    -102.20 (-0.36%)
     

Thornton Law Firm Announces Investigation into Revance Therapuetics

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, MA / ACCESSWIRE / October 18, 2021 / The Thornton Law Firm alerts investors that it is investigating Revance Therapeutics, Inc. (NASDAQ:RVNC) for potential securities violations. Investors who currently own shares or options of RVNC may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Revance for more information. Investors may also email investors@tenlaw.com or call 617-531-3917.

Thornton Law Firm LLC, Attorneys At Law logo
Thornton Law Firm LLC, Attorneys At Law logo

FOR MORE INFORMATION: www.tenlaw.com/cases/Revance

On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance Therapeutics, Inc., citing deficiencies found during an inspection at the Company's manufacturing facility for its wrinkle injection treatment, DaxibotulinumtoxinA, or DAXI (a competing product to BOTOX). Previously, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021 after Form 483 was posted to the FDA's website. Shares fell over 30% in after hours trading on October 15, 2021 following news of the FDA letter.

FOR MORE INFORMATION: www.tenlaw.com/cases/Revance

Thornton Law Firm's securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:
Thornton Law Firm LLP
1 Lincoln Street
State Street Financial Center
Boston, MA 02111

www.tenlaw.com/cases/Revance

SOURCE: Thornton Law Firm LLP



View source version on accesswire.com:
https://www.accesswire.com/668556/Thornton-Law-Firm-Announces-Investigation-into-Revance-Therapuetics